About 25% of the people who suffer from haemophilia A have no therapeutic options, because their immune system forms antibodies against clotting products that can stop bleeding. Researchers and companies in the growing US$15.8bn haemophilia market are feverishly exploring new ways to identify patients at risk and offer them alternative treatments. A series of mergers and acquisitions have changed the playing field for established markets and players.
Closing the gap in haemophilia therapy
BackgroundAbout 25% of the people who suffer from haemophilia A have no therapeutic options, because their immune system forms antibodies against clotting products that can stop bleeding. Researchers and companies in the growing US$15.8bn haemophilia market are feverishly exploring new ways to identify patients at risk and offer them alternative treatments. A series of mergers and acquisitions have changed the playing field for established markets and players.
FDA greenlights Shire’s HAE mAB Takhzyro
Latest NewsOrphan drug leader Shire plc (Dublin), has received the FDA’s approval for its antibody lanadelumab-flyo, which prevents hereditary angioedema (HAE) attacks.
Matrikines give hint to new asthma meds
Latest NewsBlocking the extracellular matrix (ECM) enzyme leukotriene A4 hydrolase (LTA4H) dampens inflammation but promotes changes in the airways of mice with allergic asthma due to accumulation of the ECM degradation product PGP.
Novo Nordisk joins Evotec as drug discovery partner
Latest NewsNovo Nordisk and Evotec have joined forces to find new drugs in the lucrative diabetes and obesity markets.
Greg Rush joins Parexel as Executive VP & CFO
AppointmentsParexel International Corporation today announced the appointment of Greg Rush as Executive Vice President and Chief Financial Officer.
Genkyotex cashes in €7.5m
Latest NewsFrench Genkyotex SA has secured an €7.5m gross financing to expand the scope of its Phase II product GKT831 in Primary Biliary Cholangitis (PBC).
Roche’s Alecensa approved in China
Latest NewsRoche AG’s ALK blocker Alecensa (alectinib) has been granted market approval by China National Drug Administration as first line NSCLC monotherapy in patients with ALK-positive non small cell lung cancer (NSCLC)
Pfizer partners with Biontech in US$425m deal
Latest NewsBioNTech AG has partnered with Pfizer to develop a mRNA-based flu vaccine.
New lupus target unraveled
Latest NewsEGFR agonists support the protective effect of Langerhans against UV-induced damage of skin cells, a hallmark of lupus erythematosus and other autoimmune and dermatologic conditions, a team of US and German researchers report.
Zelluna appoints Dr. Namir Hassan
AppointmentsZelluna Immunotherapy, a biotechnology company specializing in T-cell receptor (TCR) immunotherapies, has announced the appointment of Dr. Namir Hassan as chief scientific officer (CSO).